Financings in Brief: UroMed
This article was originally published in The Gray Sheet
UroMed: Files registration statement with the Securities and Exchange Commission for a secondary offering of 2.5 mil. shares, all of which are being offered by the company. On Oct. 18, the day the plans were announced, the issue closed at $10 a share. PaineWebber and Vector Securities International are managing the offering. Multi-center interim study results of the firm's first product, the Reliance female urinary incontinence device ("The Gray Sheet" Sept. 11, p. 10), were presented Oct. 12 at the American Urogynecologic Society annual scientific meeting ("The Gray Sheet" Oct. 16, In Brief). In its third quarter (ended Sept. 30), UroMed recorded its first-ever revenues of $404,662, which included sales of the Reliance device in Germany. UroMed booked a loss of $2.3 mil. for the period...
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”